News

The Cystic Fibrosis Foundation (CFF) opens its fourth CF FamilyCon this week, a virtual two-day free event that gives cystic fibrosis (CF) patients and their family members, caregivers, and friends an opportunity to connect, learn, and share stories of life with the genetic disorder. The Oct. 21–22 event…

The overall protein profile in the airway is altered toward a more pro-inflammatory state in people with cystic fibrosis (CF), and this difference is more pronounced in those with poorer lung function, a new study reports. “Some of these proteins might have value as markers of CF lung disease…

The Claire’s Place Foundation, a nonprofit that supports people with cystic fibrosis (CF) and their families while honoring its late founder, will present its Third Annual Clairity Ball on Oct. 22 in Santa Monica, California. Billed as “a magical evening that transforms lives,” the event raises funds…

High blood-sugar levels at night are associated with poorer lung function in adults, but not in children, with cystic fibrosis (CF), a study has found. During a week of continuous glucose monitoring, blood-sugar abnormalities were observed in almost all CF adults and children evaluated, even when other tests taken over the…

Pulmonary exacerbations — the flares that cause a sudden worsening in respiratory symptoms — contribute to the higher mortality and lung transplant rates seen in people with cystic fibrosis-related diabetes (CFRD), an analysis of adults in a U.K. CF registry reported. “These findings have important implications for clinical teams.

A Phase 1b/2 clinical trial testing WRAIR-PAM-CF1, Adaptive Phage’s experimental cocktail of bacteriophages, or viruses that selectively target and kill bacteria, is now recruiting cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infections. The study (NCT05453578) seeks to enroll up to 72 adults with CF who test positive…

A novel gene-editing treatment platform corrected the mutation that causes cystic fibrosis (CF) in multiple tissues throughout the bodies of mice, according to results of a first-of-its-kind study. “This is the first study looking at treating multiple organs affected by CF with a single gene editing treatment administered intravenously,” Alexandra…

Trikafta (elexacaftor, tezacaftor, and ivacaftor) was found to successfully lessen the microbial load in the airways of people with cystic fibrosis (CF) after one year of therapy, according to a new study. Treatment with the approved triple therapy markedly reduced the abundance of Pseudomonas aeruginosa and Staphylococcus…

Anemia is common among lung transplant recipients, and people with cystic fibrosis (CF) are at more than four times greater risk of developing anemia post-transplant compared to those with other lung diseases. That’s according to the study “Post-Transplantation Anemia and Risk of Death Following Lung Transplantation,”…

Trikafta, a triple therapy combining elexacaftor, tezacaftor, and ivacaftor, cleared Aspergillus fungus in the lungs and prevented severe infections in children and adults with cystic fibrosis (CF), a pilot study found. “These preliminary results are very encouraging and support the hypothesis that initiation of [Trikafta] therapy rapidly improves…